Contact
Please use this form to send email to PR contact of this press release:
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial
TO: